<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757311</url>
  </required_header>
  <id_info>
    <org_study_id>ONCO-COLON-TURKEY STUDY</org_study_id>
    <nct_id>NCT04757311</nct_id>
  </id_info>
  <brief_title>Metastatic Colorectal Cancer. Real-World Data Analysis.</brief_title>
  <acronym>RWD-mCRC-001</acronym>
  <official_title>The Treatment Choices, Duration and Outcomes in Patients With Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT)&#xD;
      Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, with the given rationale is to reveal treatment approaches, survival data,&#xD;
      side effect profile and their management in our country in RAS WT mCRC patients by means of&#xD;
      the real-world data collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of use anti-EGFR agents</measure>
    <time_frame>throughout of treatment, 3 years</time_frame>
    <description>The anti-EGFR agent selection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 years treatment</time_frame>
    <description>PFS three years after initiation of treatment with anti-EGFR agents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Advers events</measure>
    <time_frame>throughout of treatment, 3 years</time_frame>
    <description>Advers event of anti EGFR is defined as any untoward or unfavourable medical occurrence, including any abnormal sign, symptom, or disease, temporally associated with the patient's participation. The CTCAE v.4.0 will use in this research.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of use biologics in right side tumors.</measure>
    <time_frame>throughout of treatment, 3 years</time_frame>
    <description>Treatment selection in right side tumors.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1750</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic Colorectal Cancer Patients</arm_group_label>
    <description>All RAS wild type metastatic colorectal cancer patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have been diagnosed within 3-years period before March 2019 will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have been histologically diagnosed with mCRC&#xD;
&#xD;
          2. Patients over the age of 18&#xD;
&#xD;
          3. Patients receiving at least a cycle systemic treatment for metastatic disease&#xD;
&#xD;
          4. RAS wild type patients&#xD;
&#xD;
          5. Patients who has demographic, histopathological and clinical information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed as mCRC but only referred to BSC&#xD;
&#xD;
          2. Patients with RAS mutation&#xD;
&#xD;
          3. Patients who were included in any clinical trial except standard treatments during&#xD;
             their treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istanbul Medeniyet University Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>81450</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>Mahmut Gumus</investigator_full_name>
    <investigator_title>Mahmut Gumus, MD, Professor Medical Oncolgy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

